02/21/23 8:30 AMNasdaq : ALRN clinical triallow floatAileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic AlternativesAileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4)RHEA-AIneutral
11/30/22 7:00 AMNasdaq : ALRN low floatAileron Therapeutics Regains Compliance with Nasdaq Listing RequirementsAileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The NasdaqRHEA-AIneutral
11/10/22 8:00 AMNasdaq : ALRN low floatAileron Therapeutics Announces a 1-for-20 Reverse Stock SplitAileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, todayRHEA-AIneutral
11/01/22 8:15 AMNasdaq : ALRN earningslow floatAileron Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsActivated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in 4Q 2022 and 1Q 2023 Presented healthy volunteer study results at EORTC-NCI-AACR International Conference demonstrating potential of ALRN-6924 to preventRHEA-AInegative
10/26/22 6:05 AMNasdaq : ALRN clinical triallow floatAileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conferencep53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss) Study showed greater degree and longer duration of effect for ALRN-6924 at higher doses,RHEA-AIneutral
09/30/22 8:41 AMNasdaq : ALRN clinical triallow floatAileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022 New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells Encore presentation of data presented at Society for Investigative Dermatology in May 2022 shows: ALRN-6924 temporarily arrested the cell cycle in human scalp hair follicles andRHEA-AIneutral
09/22/22 8:00 AMNasdaq : ALRN conferenceslow floatAileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare ConferenceAileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief ExecutiveRHEA-AIneutral
09/06/22 7:00 AMNasdaq : ALRN conferenceslow floatAileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that a pre-recorded corporate presentation by Manuel Aivado, M.D.,RHEA-AIneutral
08/15/22 4:15 PMNasdaq : ALRN earningslow floatAileron Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsCompany continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trial Extended cash runway expected to support operations through end of 1Q 2024 Presented new data at the Society for InvestigationalRHEA-AIneutral
08/01/22 7:51 AMNasdaq : ALRN clinical triallow float Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast CancerEnhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutated breast cancer Key protocol enhancementsRHEA-AIneutral